Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) Cincinnati VA Medical Center |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00033033 |
The purpose of this study is to assess the efficacy and safety of reserpine for the treatment of cocaine dependence.
Condition | Intervention | Phase |
---|---|---|
Cocaine-Related Disorders Substance-Related Disorders |
Drug: Reserpine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment |
Official Title: | Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence |
Estimated Enrollment: | 140 |
Study Start Date: | July 2001 |
Estimated Study Completion Date: | May 2003 |
To assess the efficacy and safety of reserpine in reducing cocaine use in subjects with cocaine dependence. This is a double-blind, placebo-controlled, parallel-group design with a 2 week baseline period.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Be at least 18 yrs of age; DSM-4 diagnosis of cocaine dependence; treatment seeking individuals; have the ability to understand and provide written informed consent; females of child bearing potential using appropriate birth control method
Exclusion Criteria:
Additional criteria available during screening at the site.
United States, Massachusetts | |
Boston University Medical Center | |
Boston, Massachusetts, United States, 02215 | |
United States, Ohio | |
Cincinnati VA Medical Center | |
Cincinnati, Ohio, United States, 45220 | |
Dayton VA Medical Center | |
Dayton, Ohio, United States, 45428 |
Principal Investigator: | Eugene Somoza, M.D., Ph.D. | Cincinnati VA Medical Center |
Responsible Party: | NIDA ( Liza Gorgon / Clinical Trials Specialist ) |
Study ID Numbers: | NIDA-CTO-0001-1 |
Study First Received: | April 5, 2002 |
Last Updated: | August 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00033033 |
Health Authority: | United States: Food and Drug Administration; United States: Federal Government |
Cocaine-Related Disorders Reserpine Mental Disorders |
Substance-Related Disorders Disorders of Environmental Origin Cocaine |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic Uptake Inhibitors Physiological Effects of Drugs Psychotropic Drugs |
Central Nervous System Depressants Cardiovascular Agents Antihypertensive Agents Antipsychotic Agents Pharmacologic Actions Pathologic Processes Therapeutic Uses Central Nervous System Agents |